In the last trading session, 1.75 million Legend Biotech Corp ADR (NASDAQ:LEGN) shares changed hands as the company’s beta touched 0.18. With the company’s per share price at $37.84 changed hands at $0.53 or 1.42% during last session, the market valuation stood at $6.94B. LEGN’s last price was a discount, traded about -85.33% off its 52-week high of $70.13. The share price had its 52-week low at $30.17, which suggests the last value was 20.27% up since then. When we look at Legend Biotech Corp ADR’s average trading volume, we note the 10-day average is 1.21 million shares, with the 3-month average coming to 1.48 million.
Analysts gave the Legend Biotech Corp ADR (LEGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LEGN as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Legend Biotech Corp ADR’s EPS for the current quarter is expected to be -0.38.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN was in green as seen at the end of in last trading. With action 5.08%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 16.29%, with the 5-day performance at 5.08% in the green. However, in the 30-day time frame, Legend Biotech Corp ADR (NASDAQ:LEGN) is 8.95% up. Looking at the short shares, we see there were 13.11 million shares sold at short interest cover period of 9.35 days.
The consensus price target for the stock as assigned by Wall Street analysts is 91, meaning bulls need an upside of 58.42% from its current market value. According to analyst projections, LEGN’s forecast low is 83 with 94 as the target high. To hit the forecast high, the stock’s price needs a -148.41% plunge from its current level, while the stock would need to soar -119.34% for it to hit the projected low.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Data shows that the Legend Biotech Corp ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -30.80% over the past 6 months, a 10.88% in annual growth rate that is considerably lower than the industry average of 15.90%. Year-over-year growth is forecast to reach 116.16% up from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 179M. 7 analysts are of the opinion that Legend Biotech Corp ADR’s revenue for the current quarter will be 195.69M. The company’s revenue for the corresponding quarters a year ago was 79.46M and 93.99M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 125.26%. The estimates for the next quarter sales put growth at 108.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -168.48%. The 2025 estimates are for Legend Biotech Corp ADR earnings to increase by 41.49%.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.3126% or 11.49 million shares worth $508.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Select Portfolios – Health Care and Price (T.Rowe) Growth Stock Fund Inc. With 2.62 shares estimated at $99.14 million under it, the former controlled 1.43% of total outstanding shares. On the other hand, Price (T.Rowe) Growth Stock Fund Inc. held about 1.27% of the shares, roughly 2.32 shares worth around $87.87 million.
